Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Toxicological Effects
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Substrate of
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names

North America

USA: Treanda.

Drug combinations


Bendamustine Hydrochloride: C~16~H~21~Cl~2~N~3~O~2~ HCl. Mw: 394.72. (1) 1H-Benzimidazole-2-butanoic acid, 5-[bis(2-chloroethyl)amino]-1-methyl-, monohydrochloride; (2) 4-[5-[Bis(2-chloroethyl)amino]-1-methyl-1H-benzimidazole-2-yl]butanoic acid monohydrochloride. CAS-3543-75-7; CAS-16506-27-7 (bendamustine)(2004).

Pharmacologic Category

Antineoplastic Agents; Alkylating Agent. (ATC-Code: L01AA09).

Mechanism of action

Induces apoptosis via single and double strand DNA cross-linking. Active against quiescent and dividing cells. The primary cytotoxic activity is due to bendamustine (as compared to metabolites).

Therapeutic use

Treatment of chronic lymphocytic leukemia.

Pregnancy and lactiation implications

May cause fetal harm if administered during pregnancy. Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended.

Unlabeled use

Treatment of non-Hodgkin lymphoma.


Hypersensitivity to bendamustine, mannitol, or any component of the formulation.

Warnings and precautions

Bone marrow suppression (neutropenia, thrombocytopenia and anemia) is common. Rash, toxic skin reactions and bullous exanthema may occur, and may be progressive or worsen with continued treatment. Infusion reactions, which may include chills, fever, pruritus, and rash, are common; rarely, anaphylactic and anaphylactoid reactions have occurred. Infections, including pneumonia and sepsis reported. Tumor lysis syndrome may occur (may lead to life-threatening acute renal failure). Use is not recommended with renal impairment (CrCl <40 mL/minute) or moderate (AST or ALT 2.5-10 times ULN and total bilirubin 1.5-3 times ULN)/severe (total bilirubin >3 times ULN) hepatic impairment.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart